Management of Hepatorenal Syndrome

Introduction to Hepatorenal Syndrome

• The American Association for the Study of Liver Diseases recommends liver transplantation as the definitive treatment for hepatorenal syndrome, while vasoconstrictor therapy with terlipressin plus albumin is the first-line pharmacological treatment for type 1 HRS (HRS-AKI) to bridge patients to transplantation or treat those who are not transplant candidates 1, 2

Diagnostic Criteria

• The International Ascites Club recommends diagnosing HRS by excluding other causes of acute kidney injury in cirrhotic patients with advanced cirrhosis with ascites, serum creatinine >1.5 mg/dL, no improvement after at least 2 days of diuretic withdrawal and volume expansion with albumin, absence of shock, no current/recent nephrotoxic drug exposure, and absence of parenchymal kidney disease 3, 4

Treatment Algorithm

• The European Association for the Study of the Liver recommends terlipressin plus albumin as the first-line pharmacological treatment for type 1 HRS, with an initial dose of 1 mg IV every 4-6 hours, and to increase the dose stepwise to a maximum of 2 mg every 4 hours if serum creatinine doesn't decrease by at least 25% after 3 days 1, 2, 5
• The American Association for the Study of Liver Diseases suggests midodrine plus octreotide plus albumin as an alternative treatment for type 1 HRS in regions where terlipressin is unavailable, with midodrine titrated up to 12.5 mg orally three times daily, octreotide 200 μg subcutaneously three times daily, and albumin 10-20 g IV daily for up to 20 days 3, 5, 6
• The International Ascites Club recommends norepinephrine plus albumin as a treatment option for type 1 HRS, requiring an ICU setting, with a goal to increase mean arterial pressure by 15 mmHg 6, 7, 8

Liver Transplantation

• The American Association for the Study of Liver Diseases recommends liver transplantation as the definitive treatment for both type 1 and type 2 HRS, with expedited referral for transplantation recommended for patients with type 1 HRS, and survival rates approximately 65% in type 1 HRS after transplantation 1, 2

Prevention of HRS

• The European Association for the Study of the Liver recommends norfloxacin (400 mg/day) to reduce the incidence of HRS in advanced cirrhosis, and pentoxifylline (400 mg three times daily) to prevent HRS development in patients with severe alcoholic hepatitis 8, 9

Management of Hepatorenal Syndrome

Diagnostic Approach

• Diagnostic paracentesis should be performed to rule out spontaneous bacterial peritonitis, which can precipitate HRS, in patients with advanced cirrhosis and ascites 10

Pharmacological Management Algorithm

• Midodrine should be titrated up to 12.5 mg orally three times daily, as part of an alternative treatment regimen for type 1 HRS, in combination with octreotide and albumin, as recommended by the American Association for the Study of Liver Diseases 11
• Octreotide should be administered at a dose of 200 μg subcutaneously three times daily, as part of an alternative treatment regimen for type 1 HRS, in combination with midodrine and albumin, with a strength of evidence based on pilot studies 11
• Albumin should be administered at a dose of 10-20 g IV daily for up to 20 days, as part of an alternative treatment regimen for type 1 HRS, in combination with midodrine and octreotide, with a moderate strength of evidence based on clinical trials 11, 12

Definitive Treatment

• Patients with cirrhosis, ascites, and type 1 HRS should have expedited referral for liver transplantation, as recommended by the American Association for the Study of Liver Diseases, with a high strength of evidence based on clinical outcomes 12, 13

Renal Replacement Therapy

• Continuous venovenous hemofiltration/hemodialysis may be considered as a bridge to liver transplantation in selected patients with type 1 HRS, with a low strength of evidence based on limited studies 11

Important Considerations and Pitfalls

• TIPS has been reported to be effective in type 1 HRS in an uncontrolled study of 7 patients, but more evidence is needed, with a very low strength of evidence based on limited data 12

Management of Type II Hepatorenal Syndrome

Pharmacological and Non-Pharmacological Interventions

• Transjugular intrahepatic portosystemic shunts (TIPS) has been shown to improve renal function and the control of ascites in patients with type 2 HRS 14
• Renal replacement therapy may be useful in patients who do not respond to vasoconstrictor therapy and who fulfill criteria for renal support, but there are very limited data on artificial liver support systems 14

Definitive Treatment and Prevention

• Liver transplantation is the treatment of choice for both type 1 and type 2 HRS, with survival rates of approximately 65% in type 1 HRS 14
• Treatment of HRS before transplantation (with vasoconstrictors) may improve outcome after transplantation 14
• Norfloxacin (400 mg/day) can reduce the incidence of HRS in advanced cirrhosis 14
• Pentoxifylline (400 mg three times a day) has been shown to prevent the development of HRS in patients with severe alcoholic hepatitis 14
• The reduction in serum creatinine levels after treatment and the related decrease in the MELD score should not change the decision to perform liver transplantation since the prognosis after recovering from HRS is still poor 14

Treatment of Hepatorenal Syndrome

Diagnostic Criteria

• A diagnostic paracentesis must be performed to rule out spontaneous bacterial peritonitis, which can precipitate HRS 15

Alternative Treatment Options

• Midodrine plus octreotide plus albumin can be administered outside an ICU and even at home, with midodrine titrated up to 12.5 mg orally three times daily, octreotide 200 μg subcutaneously three times daily, and albumin 10-20 g IV daily for up to 20 days 15
• Norepinephrine plus albumin has a success rate of 83% reported in a pilot study, with the goal of increasing mean arterial pressure by 15 mmHg 15

Definitive Treatment

• Liver transplantation is the definitive treatment for both type 1 and type 2 HRS, with expedited referral recommended for patients with type 1 HRS, and treatment of HRS before transplantation may improve post-transplant outcomes 15

Other Treatment Considerations

• Transjugular intrahepatic portosystemic shunt (TIPS) has been reported to be effective in type 1 HRS in an uncontrolled study of 7 patients 15

Hepatorenal Syndrome Pathophysiology and Treatment

Pathophysiology

• The development of hepatorenal syndrome is contributed by four key factors, including splanchnic vasodilation, activation of the sympathetic nervous system and renin-angiotensin-aldosterone system, impaired cardiac function, and increased synthesis of vasoactive mediators affecting renal blood flow 16

Monitoring and Response Assessment

• Central venous pressure should be monitored, ideally, as part of the parameters to assess response to treatment, according to the Journal of Hepatology 16

Management of Hepatorenal Syndrome

Diagnostic Confirmation

• The American Association for the Study of Liver Diseases recommends performing diagnostic paracentesis to exclude spontaneous bacterial peritonitis, which can precipitate HRS and requires specific treatment with antibiotics plus albumin 17
• The International Club of Ascites suggests using AKI staging criteria (Stage 1: creatinine increase ≥0.3 mg/dL or 1.5-2x baseline; Stage 2: 2-3x baseline; Stage 3: >3x baseline or >4 mg/dL with acute increase ≥0.3 mg/dL) 18

First-Line Treatment: Terlipressin Plus Albumin

• The European Association for the Study of the Liver recommends starting terlipressin 1 mg IV every 4-6 hours plus albumin 1 g/kg (maximum 100 g) on day 1, followed by 20-40 g/day 18
• The American College of Gastroenterology suggests that terlipressin plus albumin achieves reversal of HRS in 64-76% of patients, with significantly superior outcomes compared to albumin alone 18

Prevention Strategies

• The American Association for the Study of Liver Diseases recommends albumin 1.5 g/kg at diagnosis of spontaneous bacterial peritonitis, then 1 g/kg on day 3, to reduce HRS incidence from 30% to 10% and mortality from 29% to 10% 17

Adjunctive Therapies

• The European Society of Intensive Care Medicine suggests considering renal replacement therapy only as a bridge to liver transplantation in patients unresponsive to vasoconstrictors 18

Hepatorenal Syndrome Treatment Guidelines

Introduction to Hepatorenal Syndrome Treatment

• The European guideline recommends terlipressin as the first-line treatment for hepatorenal syndrome, with norepinephrine as a reliable alternative, and discourages the use of midodrine/octreotide combination 19

Diagnosis and Treatment Protocol

• Diagnosis of hepatorenal syndrome is confirmed by cirrhosis with ascites, serum creatinine >1.5 mg/dL or AKI stage 2-3, no improvement after 2 days of diuretic withdrawal and albumin expansion, and exclusion of shock, nephrotoxic drugs, and structural kidney disease 19
• The treatment protocol involves choosing a vasoconstrictor based on availability and setting, with terlipressin as the first choice, followed by norepinephrine if terlipressin is unavailable and ICU access is available 19
• Norepinephrine requires ICU-level monitoring with central venous access, and dosing is 0.5-3.0 mg/hour IV, titrated to increase mean arterial pressure by 15 mmHg, combined with albumin 20-40 g/day 19

Monitoring and Duration of Treatment

• Monitoring of response involves checking serum creatinine every 2-3 days, with complete response defined as creatinine ≤1.5 mg/dL on two occasions, and partial response defined as creatinine decrease ≥25% but still >1.5 mg/dL 19
• The duration of treatment is until complete response or maximum 14 days for terlipressin, and 10-20 days for alternatives, with discontinuation of albumin if anasarca develops, but continuation of vasoconstrictors 19

Important Considerations

• Norepinephrine requires central access, and attempting peripheral administration risks tissue necrosis 19
• Monitoring for complications involves watching for cardiac/intestinal ischemia, pulmonary edema, distal necrosis with terlipressin, and requires continuous hemodynamic monitoring in ICU with norepinephrine 19

Management of Hepatorenal Syndrome

Diagnostic Confirmation

• The European Association for the Study of the Liver recommends confirming the diagnosis of hepatorenal syndrome by meeting all of the following criteria: cirrhosis with ascites, no improvement after 2 consecutive days of diuretic withdrawal and volume expansion with albumin, and absence of shock, nephrotoxic drug exposure, and structural kidney disease, in patients with serum creatinine >1.5 mg/dL 20
• Diagnostic paracentesis should be performed to exclude spontaneous bacterial peritonitis, which precipitates hepatorenal syndrome in a significant proportion of cases, and the absence of structural kidney disease should be confirmed by proteinuria <0.5 g/day, no microhematuria <50 RBCs/HPF, and normal renal ultrasound 20

Classification and Prognosis

• The International Club of Ascites recommends classifying hepatorenal syndrome into two types: type 1 HRS (HRS-AKI), characterized by rapid progression with doubling of creatinine to >2.5 mg/dL or 50% reduction in creatinine clearance to <20 mL/min within 2 weeks, and type 2 HRS, which has a more stable course with moderate renal dysfunction 20

Monitoring and Management

• The European Association for the Study of the Liver recommends monitoring patients with hepatorenal syndrome in an ICU or semi-ICU setting, with central venous pressure monitoring to guide fluid management, and checking serum creatinine every 2-3 days 20
• Patients should be managed by avoiding nephrotoxic drugs and diuretics in patients at high risk 20

Treatment of Hepatorenal Syndrome with Vasoconstrictors

First-Line Pharmacological Treatment: Terlipressin Plus Albumin

• The European Association for the Study of the Liver recommends monitoring heart rate, expecting a decrease of approximately 10 beats/minute, and central venous pressure, ideally, during terlipressin treatment 21
• The American Association for the Study of Liver Diseases suggests that norepinephrine 0.5-3 mg/hour IV continuous infusion plus albumin is an effective alternative to terlipressin, but requires ICU-level monitoring with central venous access and titration to increase MAP by 15 mmHg 21

Type 2 HRS Management

• The European Association for the Study of the Liver recommends that transjugular intrahepatic portosystemic shunt (TIPS) is more applicable in type 2 HRS than type 1 HRS due to the more stable clinical condition, and has been shown to improve both renal function and ascites control 21

Definitive Treatment: Liver Transplantation

• The American Association for the Study of Liver Diseases states that liver transplantation is the definitive treatment for both type 1 and type 2 HRS, with survival rates of approximately 65% in type 1 HRS 21
• The International Liver Transplantation Society recommends that treatment of HRS with vasoconstrictors before transplantation may improve post-transplant outcomes, and HRS reverses in approximately 75% of patients after liver transplantation alone (without combined liver-kidney transplant) 21

Prevention Strategies

• The European Association for the Study of the Liver suggests administering norfloxacin 400 mg/day to reduce the incidence of HRS in patients with advanced cirrhosis 21
• The American Association for the Study of Liver Diseases recommends administering pentoxifylline 400 mg three times daily for 4 weeks to prevent HRS development in patients with severe alcoholic hepatitis 21

Mean Arterial Pressure Targeting in Hepatorenal Syndrome

Pathophysiology and Rationale

• The pathophysiology of hepatorenal syndrome centers on extreme splanchnic vasodilation leading to decreased effective arterial volume, which triggers renal vasoconstriction, and the therapeutic goal is to reverse this splanchnic vasodilation and restore effective circulating volume, as described by the Journal of Hepatology 22

Monitoring Parameters

• Central venous pressure should be ideally monitored to guide fluid management and prevent volume overload, as recommended by the Journal of Hepatology 22
• Serum sodium concentration should increase with effective treatment, according to the Journal of Hepatology 22

Treatment Response

• The median time to response is 14 days, shorter in patients with lower baseline creatinine, as reported by the Journal of Hepatology 22
• Response is characterized by progressive reduction in creatinine, increased arterial pressure, increased urine volume, and increased serum sodium, as described by the Journal of Hepatology 22

Hepatorenal Syndrome Diagnosis and Treatment

Diagnostic Criteria

• The European Association for the Study of the Liver recommends diagnosing HRS-AKI when a patient with cirrhosis and ascites develops acute kidney injury that fails to improve after 2 consecutive days of diuretic withdrawal and albumin expansion, in the absence of shock, nephrotoxic drugs, or structural kidney disease, with a creatinine increase ≥0.3 mg/dL within 48 hours or ≥50% from baseline 23

Differential Diagnosis

• Hypovolemia accounts for 27-50% of AKI in cirrhosis and responds to volume expansion, according to the American Society of Transplantation 24
• Acute tubular necrosis accounts for 14-35% of AKI in cirrhosis, involving structural kidney damage, as noted by the American Society of Transplantation 24

Treatment Algorithm

• The European Association for the Study of the Liver recommends starting vasoconstrictor therapy plus albumin immediately upon confirming HRS-AKI diagnosis, with terlipressin plus albumin as the first-line treatment 23
• The American Association for the Study of Liver Diseases suggests that liver transplantation is the only curative treatment for HRS-AKI, with expedited referral recommended for all type 1 HRS patients 23

Prevention Strategies

• The European Association for the Study of the Liver recommends norfloxacin prophylaxis, 400 mg/day, in patients with advanced cirrhosis and low ascitic fluid protein, to reduce HRS incidence 23
• The European Association for the Study of the Liver suggests that albumin after large-volume paracentesis prevents post-paracentesis circulatory dysfunction 23

Octreotide Preferred Vasoconstrictor in Cirrhotic Patients with Ischemic Heart Disease

Safety Profile Compared with Terlipressin

• In patients with cirrhosis‑related hepatorenal syndrome (HRS) who also have known ischemic heart disease, the combination of midodrine, octreotide, and albumin is recommended as the preferred vasoconstrictor because it offers the safest cardiovascular profile, whereas terlipressin is expressly contraindicated in the presence of active coronary ischemia. [25][26]
• Terlipressin is absolutely contraindicated in patients with ongoing coronary, peripheral, or mesenteric ischemia. [25][27]26
• Common ischemic adverse effects of terlipressin include angina, arrhythmias, and digital (peripheral) ischemia, rendering it unsuitable for individuals with established ischemic heart disease. [27][26]
• The U.S. Food and Drug Administration (FDA) issues a specific warning against the use of terlipressin in patients with any known ischemic condition. 27
• After an ischemic event, terlipressin should not be re‑initiated even if symptoms resolve, due to the risk of recurrent ischemic complications. [28][29]

Octreotide Mechanism and Recommended Use

• Octreotide is designated by major gastroenterology societies as “the vasoactive drug of choice for variceal hemorrhage” because of its favorable safety profile. 25
• As a somatostatin analog, octreotide suppresses glucagon‑mediated splanchnic vasodilation and exerts direct splanchnic vasoconstriction without the systemic vasopressor effects that characterize terlipressin, supporting its safer use in patients with cardiac ischemia. [28][29]

Norepinephrine as Rescue Therapy

• When the midodrine‑octreotide regimen fails and intensive‑care monitoring is available, norepinephrine can be employed as a rescue vasoconstrictor. Central venous access and ICU‑level monitoring are required. 28
• Norepinephrine is initiated at 0.5 µg/kg/min (≈0.5 mg/h) intravenously, with titration every 4 hours by 0.5 mg/h up to a maximum of 3 mg/h, aiming to raise mean arterial pressure (MAP) by 10–15 mmHg. 28

Efficacy and Risks of Terlipressin

• Randomized controlled trials report terlipressin response rates of 36–44 % in HRS, representing the strongest efficacy evidence among vasoconstrictors. However, its ischemic complications preclude use in patients with coronary disease. [27][26]
• The CONFIRM trial demonstrated that ≈30 % of terlipressin‑treated patients experienced respiratory failure, a risk that was especially pronounced in those with underlying cardiac dysfunction. [28][29]
• Terlipressin increases systemic afterload, which can exacerbate cirrhotic cardiomyopathy or diastolic dysfunction, further limiting its suitability for patients with cardiac comorbidities. [27][26]

Prognostic Indicators and Monitoring

• Higher baseline serum creatinine predicts treatment failure with the midodrine‑octreotide regimen. [28][29]
• Each 1 mg/dL reduction in serum creatinine during therapy is associated with a 27 % decrease in mortality risk. [28][29]
• Early initiation of vasoconstrictor therapy—preferably before progression to a higher Acute‑on‑Chronic Liver Failure (ACLF) grade—improves outcomes. 27

Volume Management and Diagnostic Considerations

• Clinicians should monitor for signs of pulmonary edema from albumin administration, especially in patients with underlying cardiac dysfunction. 26
• Before diagnosing HRS, it is essential to exclude nephrotoxic drug exposure and structural kidney disease. 27
• HRS occurs exclusively in patients with cirrhosis and ascites, typically accompanied by systemic hypotension and hyponatremia. 26

Cardiovascular and Hemodynamic Factors in Hepatorenal Syndrome

Pathophysiology

• Hepatorenal syndrome (HRS) arises from splanchnic arterial vasodilation caused by portal hypertension, which produces effective arterial hypovolemia despite overall plasma‑volume expansion; this triggers sympathetic and renin‑angiotensin‑aldosterone activation, leading to intense renal vasoconstriction and functional kidney failure. 30
• Portal hypertension induces both structural (fibrosis, nodules, vascular occlusion) and dynamic (increased vascular tone) changes that raise resistance to portal blood flow, contributing to the splanchnic vasodilation cascade. 30
• Cirrhotic cardiomyopathy impairs cardiac contractility, limiting the ability to augment cardiac output in response to systemic vasodilation and thereby worsening renal hypoperfusion. [31][32]

Clinical Classification

• Type 2 HRS (chronic HRS) is frequently associated with refractory ascites, reflecting the underlying hemodynamic derangements. 30

Monitoring During Vasoconstrictor Therapy

• Terlipressin therapy typically reduces heart rate by about 10 beats/min; this change can be used to gauge pharmacologic effect. 32
• Central venous pressure monitoring is recommended during terlipressin treatment to assess intravascular volume status and guide therapy adjustments. 32
• Octreotide is recognized as “the vasoactive drug of choice for variceal hemorrhage,” offering a favorable cardiovascular safety profile when used in combination regimens for HRS. 32

Prognostic Implications of Cardiac Dysfunction

• Presence of diastolic dysfunction markedly lowers survival: approximately 95 % survival without dysfunction, 79 % with grade I dysfunction, and 39 % with grade II dysfunction. [31][32]
• Reduced cardiac output predisposes patients to acute kidney injury—including HRS—following infections such as spontaneous bacterial peritonitis. [31][32]

Strength of evidence: The cited studies provide observational and cohort data; specific grading of evidence was not reported in the source material.

Management of Hepatorenal Syndrome (HRS)

Diagnostic Confirmation

• Confirm HRS‑AKI only when all of the following are present: cirrhosis with ascites, serum creatinine > 1.5 mg/dL (or AKI stage ≥ 2), no improvement after two days of diuretic withdrawal and albumin‑based volume expansion, and absence of shock, nephrotoxic drug exposure, or structural kidney disease (proteinuria < 0.5 g/day, no micro‑hematuria, normal renal ultrasound). 33
• Perform diagnostic paracentesis immediately to exclude spontaneous bacterial peritonitis (SBP), a common precipitant of HRS. 34

First‑Line Pharmacologic Treatment (Terlipressin + Albumin)

• Initial regimen: terlipressin 1 mg IV bolus every 4–6 h (≈0.85 mg terlipressin acetate) plus albumin 1 g/kg (maximum 100 g) on day 1, then 20–40 g/day thereafter. 33
• Dose escalation: if serum creatinine has not fallen ≥ 25 % by day 3–4, increase terlipressin to 2 mg IV every 4 h (maximum 12 mg/day). 33
• Continuous‑infusion alternative: terlipressin 2 mg/day by continuous IV infusion reduces total daily dose and adverse events compared with bolus dosing. [34][33]
• Treatment duration & response criteria: continue therapy until serum creatinine ≤ 1.5 mg/dL or for a maximum of 14 days. A complete response is defined as two consecutive creatinine values ≤ 1.5 mg/dL taken ≥ 2 h apart; median time to response is 14 days. 33
• Predictors of favorable response: baseline creatinine < 3 mg/dL, bilirubin < 10 mg/dL, MAP increase ≥ 5 mmHg during therapy, lower MELD score and Child‑Pugh < 13, and younger age. 34
• Contraindications & safety checks: terlipressin is absolutely contraindicated in active coronary, peripheral, or mesenteric ischemia; obtain a baseline electrocardiogram before initiation. 33

Alternative Vasoconstrictor Regimens

• Norepinephrine + Albumin: when terlipressin is unavailable or contraindicated, norepinephrine 0.5–3 mg/h continuous IV infusion plus albumin is equally effective. Start at 0.5 mg/h and titrate every 4 h to raise MAP by 10–15 mmHg. 33
• Monitoring requirements for norepinephrine: central venous access and ICU‑level monitoring are required; peripheral administration carries a risk of tissue necrosis. [34][33]
• Midodrine + Octreotide + Albumin: in settings lacking terlipressin and norepinephrine, use midodrine 7.5–12.5 mg orally three times daily, octreotide 100–200 µg subcutaneously three times daily, and albumin 10–20 g IV daily (up to 20 days). Efficacy is substantially lower than terlipressin‑based regimens. [34][33]

Monitoring During Vasoconstrictor Therapy

• Serum creatinine every 2–3 days to assess renal response.
• Mean arterial pressure (MAP) target: increase by 10–15 mmHg.
• Heart rate: expect a decrease of ≈ 10 beats/min with terlipressin.
• Central venous pressure (when available) to guide fluid balance and avoid overload.
• Urine output and serum sodium should rise with effective treatment.
• Vigilantly watch for pulmonary edema, especially in patients with underlying cardiac dysfunction. 33

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

• TIPS is more suitable for Type 2 HRS (HRS‑NAKI) because patients are clinically more stable; it improves renal function and ascites control. 34
• Contraindications to TIPS: severe hepatic dysfunction (bilirubin > 5 mg/dL), high MELD score, significant renal dysfunction, cardiac failure, or clinically significant hepatic encephalopathy. 34
• Small studies suggest TIPS may also benefit Type 1 HRS, but its use is limited by advanced liver failure. 33

Renal Replacement Therapy (RRT)

• Initiate RRT based on clinical indications such as refractory electrolyte/acid‑base disturbances, refractory volume overload, symptomatic azotemia, or worsening renal function despite vasoconstrictors. [34][33]
• RRT is primarily a bridge to liver transplantation; outcomes in critically ill cirrhotic patients requiring RRT remain poor with high mortality. 33

Prevention Strategies

• SBP prophylaxis: give albumin 1.5 g/kg at SBP diagnosis, then 1 g/kg on day 3; this reduces HRS incidence from ~30 % to ~10 % and mortality from ~29 % to ~10 %. 34
• Provide antibiotic prophylaxis for 7 days after gastrointestinal bleeding. 34
• Large‑volume paracentesis: administer IV albumin 6–8 g per liter of ascitic fluid removed (when >5 L) to prevent post‑paracentesis circulatory dysfunction and HRS. 34

Management of Recurrent HRS

• If HRS‑AKI recurs after stopping therapy, repeat a course of vasoconstrictor treatment. 33
• Vasoconstrictors and albumin are not recommended for HRS‑NAKI (formerly Type 2 HRS) outside the AKI criteria, as recurrence after withdrawal is common and long‑term outcome data are inconclusive. 33

Clinical Pitfalls (Key Recommendations)

• Do not delay treatment: early initiation of vasoconstrictors after HRS‑AKI diagnosis improves outcomes, especially before progression to higher ACLF grades. 33
• Do not omit albumin: albumin is essential for volume expansion and anti‑inflammatory effects.
• Do not persist with ineffective therapy: if creatinine fails to decrease ≥ 25 % after 3–4 days despite dose escalation, consider alternative vasoconstrictors, RRT, or transplantation. 33
• Do not overlook precipitating factors: always rule out and treat SBP, gastrointestinal bleeding, and discontinue nephrotoxic drugs. 34

Albumin Use in Hepatorenal Syndrome Management

Diagnostic Volume Expansion

• In patients with cirrhosis, a diagnostic trial of albumin 1 g/kg (capped at 100 g) administered daily for two consecutive days after stopping all diuretics helps exclude prerenal AKI and differentiate HRS‑AKI from volume‑responsive azotemia. [35][36]
• Albumin is superior to saline for restoring effective arterial blood volume in cirrhotic patients with ascites. 35
• Failure of serum creatinine to improve after this albumin challenge constitutes a diagnostic criterion for HRS‑AKI. 35

Therapeutic Dosing Protocol (combined with vasoconstrictor)

• Loading dose (Day 1): Albumin 1 g/kg body weight (maximum 100 g) given intravenously as a 20 % or 25 % solution. 36
• Maintenance dosing (Day 2 onward): Albumin 20–40 g per day intravenously, adjusted according to the patient’s volume status, and continued until a complete renal response (serum creatinine ≤ 1.5 mg/dL on two measurements ≥ 2 h apart) or a maximum of 14 days. [36][37]

Vasoconstrictor Combinations (always paired with albumin)

• First‑line: Terlipressin 1 mg IV every 4–6 h (≈ 0.85 mg terlipressin acetate); if serum creatinine has not fallen ≥ 25 % by days 3–4, the dose may be escalated to 2 mg IV every 4 h. 37
• Alternative: Norepinephrine continuous IV infusion 0.5–3 mg/h, titrated to raise mean arterial pressure by 10–15 mmHg; requires ICU setting and central venous access. 37
• Third‑line (when terlipressin unavailable): Midodrine 7.5–12.5 mg orally three times daily plus octreotide 100–200 µg subcutaneously three times daily, together with albumin 10–20 g/day for up to 20 days. 37

Monitoring & Volume‑Status Assessment

• The 2024 American Gastroenterological Association (AGA) guideline notes that the optimal method to assess volume status remains uncertain; albumin dosing should be individualized to avoid both under‑resuscitation and volume overload. [35][36]
• When available, central venous pressure measurement can guide fluid balance and help prevent overload. 35
• Clinicians must vigilantly monitor for pulmonary edema, especially in patients with underlying cardiac dysfunction or cirrhotic cardiomyopathy. [36][38]
• The ATTIRE trial demonstrated that aggressive albumin dosing (approximately ten‑fold higher than standard control dosing) markedly increased the incidence of pulmonary edema. [36][38]

Pitfalls & Contraindications

• Fixed albumin dosing without assessment of volume status can lead to either volume overload (risking pulmonary edema) or insufficient therapy; dosing must be tailored to the individual’s hemodynamic profile. [35][36]
• Albumin should not be used for uncomplicated ascites or after large‑volume paracentesis in patients with HRS, as these are separate indications with different dosing recommendations. [39][37]38

Mechanistic Rationale

• Albumin provides both plasma‑volume expansion and anti‑inflammatory effects that are essential for counteracting the splanchnic vasodilation and effective arterial hypovolemia that underlie HRS pathophysiology. 35

Midodrine–Octreotide–Albumin Therapy for Hepatorenal Syndrome: Evidence‑Based Guidance

1. Treatment Hierarchy and Indications

• Midodrine + octreotide + albumin should be reserved for patients in whom terlipressin or norepinephrine are unavailable, because it achieves HRS reversal in only ≈ 28–29 % of cases versus ≈ 70 % with terlipressin. 40
• First‑line therapy (when available) is terlipressin + albumin, which reverses HRS in ≈ 64–76 % of patients. 40
• Second‑line therapy is norepinephrine + albumin; this regimen requires intensive‑care unit (ICU) admission and central venous access. 40, 41
• Third‑line therapy is the combination of midodrine, octreotide, and albumin, to be used only when the first two options cannot be administered. 40

2. Dosing Recommendations

• Continuous infusion of terlipressin at 2 mg day⁻¹ reduces adverse events compared with bolus dosing. 40

3. Monitoring Parameters

• Renal response – Partial response is defined as regression of AKI stage with serum creatinine still ≥0.3 mg/dL above baseline. 40
• Hemodynamics – Central venous pressure should be monitored when feasible to avoid volume overload. 40
• Safety – Screen for cardiac, peripheral, or mesenteric ischemia; obtain a baseline electrocardiogram before initiating therapy. 40

4. Preferred Use in Specific Settings

• In resource‑limited environments where terlipressin is unavailable or unaffordable, the midodrine + octreotide + albumin regimen is recommended as a viable alternative. 40, 41
• This regimen can be administered outside the ICU and even in outpatient or home settings, unlike norepinephrine.

5. Predictors of Treatment Failure

• Baseline serum creatinine > 3 mg/dL is associated with a lower likelihood of HRS reversal. 41
• Presence of severe systemic inflammation (greater number of extra‑renal organ failures) reduces response rates. 40, 41
• Severe cholestasis (bilirubin > 10 mg/dL) predicts poorer treatment efficacy. 41

6. Management of Recurrent HRS

• If HRS‑AKI recurs after cessation of therapy, a repeat course of vasoconstrictor(s) plus albumin should be administered. 40
• Patients with continuous recurrence may require long‑term, repeated hospitalizations for ongoing vasoconstrictor therapy. 41
• For type 2 HRS (non‑AKI chronic form), vasoconstrictors and albumin are not recommended outside AKI criteria, as long‑term benefit is unproven. 40

Albumin Management and Vasoconstrictor Therapy in Anasarca Patients with Suspected HRS‑AKI

Diagnostic Albumin Challenge (First 48 h)

• Administer intravenous albumin 1 g/kg (maximum 100 g) on day 1, followed by 20–40 g on day 2 after stopping all diuretics to differentiate HRS‑AKI from volume‑responsive prerenal azotemia; lack of improvement in serum creatinine after 48 h confirms HRS‑AKI. 42

Albumin Management After HRS‑AKI Confirmation

• Once HRS‑AKI is confirmed, albumin dosing should be individualized according to the patient’s volume status rather than continued at a fixed dose. 42
• The 2024 American Gastroenterological Association (AGA) guideline advises that routine fixed‑dose albumin in any AKI patient may be insufficient or may precipitate volume overload (e.g., pulmonary edema). 42

Monitoring Parameters

• Central venous pressure (CVP) can be used, when available, to guide fluid balance and avoid circulatory overload, recognizing that CVP is an imperfect surrogate for cardiac output in cirrhosis. 43
• Clinicians should vigilantly monitor for signs of pulmonary edema (dyspnea, hypoxemia, crackles, radiographic changes) during albumin therapy. 42

Vasoconstrictor Therapy (Must Continue Even If Albumin Is Stopped)

• Vasoconstrictors are the primary therapeutic agents for HRS‑AKI and must be maintained for the full treatment course regardless of albumin discontinuation. [42][44]

First‑Line: Terlipressin

• Initiate terlipressin 1 mg IV every 4–6 h; if serum creatinine has not fallen ≥25 % by days 3–4, increase to 2 mg IV every 4 h (maximum 12 mg/day). 43
• A continuous infusion of terlipressin at 2 mg/day reduces adverse events compared with intermittent bolus dosing and provides more stable portal‑pressure reduction. 43
• Continue terlipressin for up to 14 days or until a complete renal response is achieved (serum creatinine ≤1.5 mg/dL on two consecutive measurements). 43

Second‑Line: Norepinephrine

• Use norepinephrine 0.5–3 mg/h as a continuous IV infusion when terlipressin is unavailable or contraindicated. 42
• Administration requires ICU‑level monitoring with central venous access; titrate every 4 h to raise mean arterial pressure by 10–15 mmHg. 42

Guideline Evolution and Evidence Strength

• The 2024 AGA guideline departs from the 2018 European Association for the Study of the Liver (EASL) recommendation, which advised continuing a fixed albumin dose of 20–40 g/day throughout HRS‑AKI treatment; the newer guidance emphasizes individualized albumin dosing based on volume status. [43][42]

All facts are drawn from peer‑reviewed sources with the indicated citation numbers.